Brenus Pharma

Brenus Pharma Develops Immune Therapies Based on Anticancer Cells, Aiming to Generate Allogeneic Cell Vaccines for Solid Tumor Immunotherapy. The company's immunotherapy achieves a risk-reduction strategy through the generation of multiple drug candidates, cost and time efficiency expansion, non-competitive market access, standard care, robust global intellectual property dissemination, and a highly skilled team supported by world-renowned oncologists, enabling oncologists to induce responses after education to identify tumor-associated antigens and tumor-specific antigens expressed during chemotherapy or radiotherapy.